Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
24/03/2026 17:25
March 24 (Reuters) - Transgene SA TRNG.PA: TRANSGENE SA - MYVAC PLATFORM TO INITIATE PHASE 1 TRIAL IN SECOND INDICATION IN 2026 TRANSGENE SA - 3-YEAR DISEASE-FREE SURVIVAL FOLLOW-UP FOR HNSCC EXPECTED IN Q2/Q3 2026 Source text: ID:nGNX6JGw8c Further company coverage: TRNG.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs